Chalcomoracin and moracin C, new inhibitors of Staphylococcus aureus enoyl-acyl carrier protein reductase from Morus alba

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 5, 2012, Pages 791-795

  Kim, Yu Jin ^a   Sohn, Mi Jin ^a   Kim, Won Gon ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Chalcomoracin; Enoyl acyl carrier protein reductase; FabI; Fatty acid synthesis; Moracin C; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; CHALCOMORACIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); MORACIN C; MULBERRY EXTRACT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; IC 50; MORUS ALBA; NONHUMAN; PLANT LEAF; STAPHYLOCOCCUS AUREUS;

ACETIC ACID; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZOFURANS; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); FATTY ACIDS; MICROBIAL SENSITIVITY TESTS; MORUS; PLANT EXTRACTS; PLANT LEAVES; PROTEIN BIOSYNTHESIS; STAPHYLOCOCCUS AUREUS; STILBENES;

EID: 84861206271     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.791     Document Type: Article

References (25)

1. Naowaboot J, Pannangpetch P, Kukongviriyapan V, Kukongviriyapan U, Nakmareong S, Itharat A. Mulberry leaf extract restores arterial pressure in streptozotocin-induced chronic diabetic rats. Nutr. Res., 29, 602-608 (2009).
2. Butt MS, Nazir A, Sultan MT, Schroen K. Morus alba L. nature's functional tonic. Trends Food Sci. Technol., 19, 505-512 (2008).
3. Fukai T, Kaitou K, Terada S. Antimicrobial activity of 2-aryl-benzofurans from Morus species against methicillin-resistant Staphylococcus aureus. Fitoterapia, 76, 708-711 (2005).
4. Campbell JW, Cronan JE Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol., 55, 305-332 (2001).
5. Heath RJ, Rock CO. Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs, 5, 146-153 (2004).
6. Moir DT. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr. Drug Targets Infect. Disord., 5, 297-305 (2005).
7. Zhang YM, White SW, Rock CO. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem., 281, 17541-17544 (2006).
8. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature, 394, 531-532 (1998).
9. Rozwarski DA, Grant GA, Barton DHR, Jacobs WR Jr, Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science, 279, 98-102 (1998).
10. Heerding DA, Chan G, DeWolf WE Jr, Fosberry AP, Janson CA, Jaworski DD, McManus E, Miller WH, Moore TD, Payne DJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Smith W, Takata DT, Vaidya KS, Yuan CCK, Huffman WF. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett., 11, 2061-2065 (2001).
11. Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CCK, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF. Discovery of aminopyridinebased inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem., 45, 3246-3256 (2002).
12. Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf Jr WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CCK, Huffman WF. Discovery of a novel and potent class of FabIdirected antibacterial agents. Antimicrob. Agents Chemother., 46, 3118-3124 (2002).
13. Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem., 46, 1627-1635 (2003).
14. Ling LL, Xian J, Ali S, Geng B, Fan J, Mills DM, Arvanites AC, Orgueira H, Ashwell MA, Carmel G, Xiang Y, Moir DT. Identification and characterization of inhibitors of bacterial enoylacyl carrier protein reductase. Antimicrob. Agents Chemother., 48, 1541-1547 (2004).
15. Zheng CJ, Sohn MJ, Lee S, Hong Y-S, Kwak J-H, Kim W-G. Cephalochromin, a FabI-directed antibacterial of microbial origin. Biochem. Biophys. Res. Commun., 362, 1107-1112 (2007).
16. Zheng CJ, Sohn M-J, Kim W-G. Vinaxanthone, a new FabI inhibitor from Penicillium sp. J. Antimicrob. Chemother., 63, 949-953 (2009).
17. Tasdemir D, Lack G, Brun R, Rüedi P, Scapozza L, Perozzo R. Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J. Med. Chem., 49, 3345-3353 (2006).
18. Zhang YM, Rock CO. Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J. Biol. Chem., 279, 30994-31001 (2004).
19. Miesel L, Greene J, Black TA. Genetic strategies for antibacterial drug discovery. Nat. Rev. Genet., 4, 442-456 (2003).
20. Takasugi M, Nagao S, Masamune T, Shirata A, Takahashi K. Chalcomoracin, a natural Diels-Alder adduct from diseased mulberry. Chem. Lett., 9, 1573-1576 (1980).
21. Takasugi M, Nagao S, Ueno S, Masamune T, Shirata A, Takahashi K. Moracin C and D, new phytoalexins from diseased mulberry. Chem. Lett., 7, 1239-1240 (1978).
22. Sharma R, Sharma A, Shono T, Takasugi M, Shirata A, Fujimura T, Machii H. Mulberry moracins: scavengers of UV stress-generated free radicals. Biosci. Biotechnol. Biochem., 65, 1402-1405 (2001).
23. Zheng CJ, Yoo J-S, Lee T-G, Cho H-Y, Kim Y-H, Kim W-G. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett., 579, 5157-5162 (2005).
24. Nair D, Memmi G, Hernandez D, Bard J, Beaume M, Gill S, Francois P, Cheung AL. Whole-genome sequencing of Staphylococcus aureus strain RN4220, a key laboratory strain used in virulence research, identifies mutations that affect not only virulence factors but also the fitness of the strain. J. Bacteriol., 193, 2332-2335 (2011).
25. Sivaraman S, Zwahlen J, Bell AF, Hedstrom L, Tonge PJ. Structureactivity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs. Biochemistry, 42, 4406-4413 (2003).